Q4 26 Test Volumes Rise with Medicare Policy Momentum

10/04/2026 09:23 NZST, GENERALP

Q4 26 TEST VOLUMES RISE WITH MEDICARE POLICY MOMENTUM

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) releases its investor update for the three months to the end of March 2026 (Q4 26) today showing an increase in test volumes as strategic momentum for a Medicare policy change mounts.

The investor update also provides details on several key strategic milestones achieved in the quarter:

• Details of the strong support for Cxbladder voiced by the panel of experts assembled by Novitas at its Contractor Advisory Committee (CAC) on 19 February, an event that typically precedes the drafting of new medical policy in the form of a local coverage determination (LCD). This development has reinforced the company’s confidence that a positive draft LCD will be forthcoming before the end of Q2 27

• Significant success with commercial payers in the US and the Asia Pacific notably:

o Cxbladder Triage is now covered by Blue Cross Blue Shield (BCBS) North Carolina (~3.4m covered lives) and BCBS South Carolina (~762k covered lives). These policy changes, in one of the largest health payer networks in the US, mirror the coverage language from Avalon Healthcare Systems published in February, demonstrating the influence that positive policy from third parties can have on commercial payers

o Cxbladder Monitor is now covered by Highmark, an independent licensee of the BCBS association and one of the largest BCBS plans in the US (covering 7 million lives)

o Singapore General Hospital the largest and oldest hospital in the country, serving a population of more than one million patients annually, has decided to incorporate Triage, Triage Plus, and Monitor into patient care

o Townsville University Hospital, a leading care provider in Queensland serving a patient population of 700,000, has begun clinical use of Triage Plus and Monitor

• Progress protecting Triage Plus intellectual property with the filing of a PCT application

Total laboratory throughput (TLT) in Q4 26 rose 2.7% on Q3 26 to 5,582 tests from 5,435 tests in Q3 26. US TLT was up 1.0% to 4,064 from 4,025 tests in Q3 26 with increasing usage primarily reflecting growth in volumes through the Kaiser Permanente Southern California system. APAC volumes rose 7.7% to 1,518 tests from 1,410 in Q3 26 lifted by an increase in commercial test volumes and an increase in clinical study volumes.

The improvement in test volumes over the quarter comes despite the disruption of transitioning US customers from Cxbladder Detect to Triage, the challenges of selling a product not covered by Medicare and a reduction in operating days in the US, where operations during the quarter were disrupted by a series of winter storms.

At the same time sales have been hampered by capital preservation initiatives that saw a reduction in our sales force to 7.7 FTEs from 12.0 FTEs in Q3 26. Product mix was relatively stable against the prior quarter, with Triage dominating volumes, reflecting the shift away from Detect in the US.

Our sales force efficiency metric of tests per sales FTE increased to 530 from 335 in Q3 26 driven primarily by our policy to limit the backfilling of not yet profitable territories given the non-coverage determination. The number of ordering clinicians fell to 747 from 834 ordering clinicians in Q3 26. Tests per unique ordering clinician were up to 5.4 from 4.8 in Q3 26.

Pacific Edge Chief Executive Dr Peter Meintjes says in the update: “Pacific Edge enters the new financial year on the cusp of a major commercial inflection point. Backed by robust clinical evidence, the endorsement of our tests in clinical guidelines, and growing momentum in clinical opinion, we have firmly established ourselves as the first mover and market leader in bladder cancer diagnostics.”

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:

Investors:

Dr Peter Meintjes

Chief Executive

Pacific Edge

P: 022 032 1263

Media:

Richard Inder

The Project

P: +64 21 645 643

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association’s Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.